Member Info for liamnicholas

@Taff

Better over on the ADVFN thread mate

Superb post

Hinkais

that's a very good spot

well done ..

https://twitter.com/Lium__/status/1020292466879148032

reduced on Monday before the epic rise

it wasn't just me waiting for the drop to top up at 2.4

For those who haven't seen this from the weekend

http://www.heraldscotland.com/business_hq/16339604.display/

Published 5 hours ago & a Superb read Instilled a lot of confidence heraldscotland.com/business_hq/16339604.heart-valve-pioneer-aortech-international-returns-to-its-scottish-roots/

I love nothing more than a company with exponential potential

Low free float available for trading combined with a very low market cap

= recipe for success

this is just the beginning

No posts Lovely !!

These are the excerpts from the recent broker note. Have to suspect this is now in advanced stages...

A £2.5m annual royalty would be valued at a PE ratio of 25-50 times I suspect. i.e. we'd be looking at a Market Cap of £62.5-125m just on the Breast IP ! (ARM was valued at 50-100x PE on its Royalty income)

"A leading device manufacturer is investigating using AorTech's technology for its next generation products.

Development plan
AorTech is in the early stages of an investigatory programme with a breast implant business that has identified the opportunity to develop new technology to drive its business in the future.

Opportunities for Aortech
This project requires little investment by AorTech but, if successful, would result in either a very attractive licence and royalty income or a JV opportunity to disrupt current technologies and supply chains. Not assumed in our projections, but as an indication of the potential value is that a 5% royalty on a 5% global market share would generate an income stream of £2.5m per annum to AorTech."

3 (THREE !) potential game-changers to AorTech tech/IP in the breast implant/reconstruction market

landy9 04 Jul '18 - 08:15 - 453 of 487

Breast implant tech has not really changed over the last 40 years. AORTECH has three potential game changers
1. SHELL
A more durable and abrasion resistant shell material, so improving safety and life of implant
2. FILLER
A gel compound that is much lower density than silicon gel, thus reducing the weight of the implant giving a more natural feel. They also have a foaming tech that would also reduce density of implant.
3. PROCEDURE
A process for filling an implant in situ, thus making the procedure minimally invasive with less scarring.

Some great posts over on ADVFN might work checking it out for those who only use this BB.

The better it gets

this was priced to go pop at 2m market cap not long ago looking at the May stats

https://www.londonstockexchange.com/statistics/markets/aim/aim.htm

The lowest valued medical device company on AIM

I can't believe how much of a turn around story there is here to develop and unfold.

2 x new partnerships
1 x new patent
£60m on research & Development
Profitable
Self sufficient licenses pays over heads for operations
Licences are below market cap value (may rns)

lovely

Just how we like it

When people actually do some research here and recognize the potential v the current market cap v current shares available in issue.

Moving on thin air now

New Chapter



The long-running litigation dispute created a number of uncertainties for AorTech and its shareholders and at the time of announcing results for the year to 31 March 2017 the share price was implying that AorTech was likely to fail.



The recent trading results should indicate to shareholders that the business is on a more stable footing and the risk of failure diminished. The cash position improved during the six months to 30 September 2017 and at the end of November 2017 had further increased to $328,000. As a result of the conclusion of the litigation, AorTech will have certain costs to pay and make reimbursements to our insurance provider. However, we anticipate that the net cash position should improve further.



The Board has conducted a thorough review of the Company's IP and where it fits into the medical device market, leading to the conclusion that there are a number of opportunities available to grow AorTech's business. A detailed strategic plan to allow AorTech to commercialise its platform technology is currently being considered and we will report to shareholders when the process is concluded.



We have the opportunity of putting past issues behind us and building on the core IP within the business. As part of this "fresh start", I am delighted to welcome Stockdale Securities as our new Nominated Adviser and broker and look forward to working with them to help AorTech reach its true potential.



Bill Brown, Chairman 11 December 2017

- says it all

This is just the beginning of the new era

Solid plan in place - As mentioned on 21st May

the Company intends to enter into a development and manufacturing agreement with RUA Medical, a medical textiles manufacturer, and a development contract with Vascular Flow Technologies, a medical device development company. If successfully developed and approved by the relevant regulatory authorities, the Company proposes to employ what the Directors believe to be a lean sales and marketing strategy for its products, a distribution model to provide access to hospital markets and OEM sales of devices to other medical device companies.

19th June - Development Agreement signed with Vascular Flow Technologies Limited ("VFT")

28th June - Development and Supply Agreement with RUA Medical

Bonus of 26th June - Bill Brown, Chairman of AorTech said: "We are delighted that this US Patent has been issued extending further AorTech's world class portfolio of biostable polymers for medical device use."

So the next news includes a lean sales and marketing strategy for its products, a distribution model to provide access to hospital markets and OEM sales of devices to other medical device companies.

With the boarding of : -

John Ely (NED - Heart Valve Expert)
Geoffrey Berg (NED - Cardiovascular Expert)
David Richmond (NED - Product Development Expert)
Craig Dunlop & team at VFT (Consultant - Valve Engineering)
Edwin Lindsay at Compliance Solutions (Regulatory Affairs)

What's not to like?

RNS released

Development and Supply Agreement with RUA Medical

AorTech (AIM: AOR), the biomaterials and medical device IP company, is pleased to announce that it has signed an agreement with RUA Medical, the trading name for Culzean Medical Devices Limited, for the development and supply of its soft tissue pericardial patch and large bore vascular graft.

AorTech has identified opportunities within the medical device sector to improve the performance and functionality of certain devices by incorporating the biostable medical grade polymer (Elast-EonTM) into those devices. AorTech has appointed RUA Medical as its development and manufacturing partner to bring the immediate opportunities from this platform technology to market.

Bill Brown, Chairman of AorTech said: "In anticipation of entering into this agreement, the AorTech and RUA Medical teams have gone through a detailed project planning process. This process has confirmed to AorTech that RUA Medical is the ideal partner for this project and that its unique combination of R&D, project management, regulatory and manufacturing expertise should help us deliver the soft tissue pericardial patches and large bore grafts to market in a highly efficient manner."

Caroline Stretton, Chief Executive Officer of RUA Medical said: "The team at RUA Medical is delighted to be partnering with AorTech on the development and supply of their transformational devices. Superior safety and performance, in conjunction with secure supply, will afford spectacular improvements to the quality of life of end users. RUA Medical also recognises the exciting future prospect of exploiting further medical device opportunities within AorTech's novel platform technology."

That's what I thought.

From the 14th June RNS : -

"Following Admission, the Company will have 14,686,608 Ordinary Shares in issue admitted to trading on AIM. This figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules."

With a market cap of £7m

I couldn't believe my eyes

this last week

https://investegate.co.uk/aortech-inter-plc/rns/development-agreement-signed/201806190930038386R/

Bill Brown, Chairman of AorTech, said: "In partnering with the team at VFT, AorTech now has access to Europe's leading experts in the combined field of medical imaging, guided Finite Element Analysis and Computational Fluid Dynamics. Combining the design history with this ground breaking imaging analysis should much improve the quality of the product design, reliability and performance."

Craig Dunlop, General Manager and Director of VFT, said: "The team at VFT has been very impressed with the quantity and quality of data that AorTech has been able to demonstrate to us. We are very excited to be a key partner in the development of the next generation of prosthetic heart valves which should represent not only a step change in performance, but dramatically reduce the cost to manufacture these life enhancing devices."


now this today

https://investegate.co.uk/aortech-inter-plc/rns/new-patent-issued/201806261249266329S/

Also TR1's with positions being taken

I can only see this going one way ... Well done to those who have been in a while and making serious gains.

Looks great!

Love seeing PI's getting the chance to get their money back :) Well done

I first had these at 0.18 and got lucky .. Did a lot of reading and research on this company, and it's great to see they are still discovering! The amount of licences they have and areas they are in, is as safe as they come IMO

This is most def one for the future, accumulating dips.I 've always believed GH's plan is to sell out for huge profits .. Not even maximising the potential, but selling every 100% owned licence.

Taken a battering on Foot Asylum this week, so grabbed some of these off the back of that RNS and looking forward to the next few weeks to make my losses back.

Well done those who have held, patience and nerves of steel from the EG/Newmont fiasco

Remember to bank profits on the way up!